Shams Noori Pharma Trading Company

Shams Noori Pharma Trading Company is a prominent pharmaceutical importer based in Kabul, Afghanistan. Established to address the growing demand for quality medicines, the company plays a pivotal role in the Afghan pharmaceutical distribution network. Operating as a primary wholesaler, Shams Noori Pharma Trading Company sources a diverse range of pharmaceutical products from international suppliers, ensuring their availability across Afghanistan. The company's strategic location in Kabul facilitates efficient distribution throughout the country, catering to both urban and rural healthcare facilities.

The company's headquarters are situated at Office No. 2 3, Haqmal Plaza, Hotel 3rd Part of Khair Khana, District 11, Kabul, Afghanistan. This central location enables Shams Noori Pharma Trading Company to effectively manage its operations and maintain strong relationships with suppliers and customers alike.

Shams Noori Pharma Trading Company operates a centralized distribution model from its Kabul headquarters. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Kabul suggests a well-organized distribution network capable of reaching various regions within Afghanistan. The company's extensive import activities, with a total of 328 shipments from India, indicate a robust logistics framework supporting its operations.

As a primary wholesaler, Shams Noori Pharma Trading Company serves as a critical link in Afghanistan's pharmaceutical supply chain. By importing a wide array of pharmaceutical products, the company ensures that essential medicines are accessible to healthcare providers across the country. Its role is vital in maintaining the flow of medical supplies, thereby supporting the overall healthcare infrastructure in Afghanistan.

Shams Noori Pharma Trading Company exhibits a high degree of sourcing concentration, with 68.2% of its total import value ($10.8 million) attributed to COMBITIC GLOBAL CAPLET PRIVATE LIMITED. This significant reliance on a single supplier suggests a strategic partnership aimed at ensuring consistent product quality and supply. However, such concentration also poses potential risks, including supply chain disruptions in the event of issues with the primary supplier. The company's diversified sourcing from 15 unique Indian suppliers indicates a proactive approach to mitigating these risks by not solely depending on one source.

The resilience of Shams Noori Pharma Trading Company's supply chain is bolstered by its relationships with multiple Indian suppliers, including COMBITIC GLOBAL CAPLET PRIVATE LIMITED, ANCALIMA LIFESCIENCES LIMITED, and INNOVA CAPTAB LIMITED. This diversification allows the company to adapt to potential disruptions from any single supplier. While specific details about backup suppliers and shipping routes are not publicly available, the company's extensive import activities and supplier network suggest a well-structured and resilient supply chain capable of maintaining steady product availability in Afghanistan.

The sourcing pattern of Shams Noori Pharma Trading Company, characterized by a dominant supplier relationship complemented by a diversified supplier base, positions the company to leverage favorable terms and ensure product consistency. For Indian exporters, this presents an opportunity to establish partnerships with a key player in Afghanistan's pharmaceutical market. By offering competitive pricing, reliable quality, and adherence to regulatory standards, Indian suppliers can enhance their appeal to Shams Noori Pharma Trading Company, potentially expanding their market presence in Afghanistan.

The Afghanistan Food and Drug Authority (AFDA), operating under the Ministry of Public Health, is the primary regulatory body overseeing pharmaceutical imports into Afghanistan. The AFDA is responsible for issuing licenses to pharmaceutical importers, ensuring compliance with national standards, and maintaining the quality and safety of medicines available in the country. The regulatory framework governing pharmaceutical imports includes the National Licensed Medicines List, which specifies the medicines authorized for importation and distribution within Afghanistan. (afda.gov.af)

To import pharmaceutical products into Afghanistan, companies must obtain an activity license from the General Directorate of Pharmacy Affairs (GDPA) under the Ministry of Public Health. This license is contingent upon compliance with guidelines on good manufacturing practices (GMP), distribution, and storage. Additionally, importers are required to secure an import permit from the GDPA, ensuring that only medicines registered in the National Licensed Medicines List are imported and distributed within Afghanistan.

Imported pharmaceutical products must undergo quality control measures, including batch testing and stability assessments, to ensure their safety and efficacy. Labeling requirements stipulate that product information be provided in the official languages of Afghanistan, with clear instructions for use, dosage, and storage. Serialization mandates are enforced to enhance traceability and prevent counterfeit products from entering the market. These measures are part of the AFDA's efforts to maintain high standards in the pharmaceutical sector. (afda.gov.af)

Between 2024 and 2026, the Afghanistan Food and Drug Authority implemented several policy changes affecting pharmaceutical imports. These included updates to the National Licensed Medicines List, introducing new medicines and removing outdated ones to align with current medical practices. Additionally, the AFDA enhanced regulatory oversight by tightening import licensing requirements and enforcing stricter compliance with GMP standards. These changes aim to improve the quality and safety of pharmaceutical products available in Afghanistan. (afda.gov.af)

Shams Noori Pharma Trading Company's focus on importing products in the gastrointestinal, respiratory & OTC, and antihistamines & allergy therapeutic categories aligns with the prevalent health concerns in Afghanistan. The significant import value of Domperidone, a medication used to treat nausea and vomiting, indicates a high demand for gastrointestinal treatments. Similarly, the inclusion of Phenylephrine, Omeprazole, Diclofenac, and Cetirizine reflects the company's strategy to address common respiratory issues, pain management, and allergic reactions prevalent among the Afghan population.

Shams Noori Pharma Trading Company primarily sources generic pharmaceutical formulations from India, focusing on finished dosage forms such as tablets, capsules, syrups, and injections. This strategy allows the company to offer cost-effective medications without compromising on quality. India's well-established pharmaceutical manufacturing sector, known for its adherence to international quality standards, makes it a reliable source for these products.

By importing a diverse range of pharmaceutical products, Shams Noori Pharma Trading Company serves multiple segments of the Afghan market, including retail pharmacies, hospitals, and government tenders. Its extensive distribution network ensures that essential medicines are accessible to various healthcare providers, thereby supporting the overall healthcare infrastructure in Afghanistan.

There is a realistic opportunity for new Indian suppliers to collaborate with Shams Noori Pharma Trading Company. The company's diversified sourcing strategy indicates openness to establishing relationships with additional suppliers who can meet quality standards and regulatory requirements. Potential gaps in the company's current sourcing include the need for specialized formulations or products not currently offered by existing suppliers. Indian exporters can explore these opportunities by aligning their product offerings with the therapeutic categories prioritized by Shams Noori Pharma Trading Company.

Indian exporters seeking to supply Shams Noori Pharma Trading Company must ensure that their products are registered in the National Licensed Medicines List of Afghanistan. Compliance with international quality standards, such as WHO GMP or EU GMP certifications, is essential. Additionally, adherence to labeling requirements, including the use of official Afghan languages and compliance with serialization mandates, is necessary to meet regulatory standards.

To establish a partnership with Shams Noori Pharma Trading Company, Indian exporters should initiate contact through formal channels, providing detailed product information, quality certifications, and compliance with Afghan regulatory standards. Participating in tenders and responding to requests for proposals can also be effective strategies. Understanding the regulatory filing process and preparing for the necessary documentation will facilitate smoother entry into the Afghan market. Given the complexities of international trade and regulatory compliance, a timeline of several months may be required to establish a successful partnership.